A conversation about what comes next
Where sound and AI meet CGMPs, and CGMPs meet practice — in pharma and beyond.
Knowledge, in the mix.
Latest episodes · Sponsored by Tailwind Pharma
Nov 2, 2026
The investigator leaves and someone says, "Well, glad that's over." That is usually your cue to reopen the action tracker. When the FDA walks out your door, who actually decides your facility’s fate? Is it the field investigator who walked the cleanroom, or an office at White Oak you’ve never seen?
01 / The conversation
A pharmaceutical regulatory affairs podcast for the people responsible for quality—and anyone curious about the rules behind medicines.
The Regulatory Mix brings FDA guidance, current Good Manufacturing Practices, and public enforcement actions into focus. Episodes pair clear overviews with deeper analysis of the documents and developments shaping pharmaceutical manufacturing and compounding.
For seasoned professionals and quality-minded newcomers alike, the aim is practical context without losing the nuance that matters.
01 / Credible
Grounded in public documents.
02 / Curious
Open to the questions that matter.
03 / Clear
Context you can carry into your work.
02 / In the mix
The issues behind today’s quality decisions. Each topic is approached as a working question for regulated teams—not simply a headline or a summary of agency language.
Clear overviews of the documents, expectations, and policy shifts shaping pharmaceutical quality and regulatory work.
Practical discussion of public FDA actions and what the underlying observations can teach quality and operations teams.
Focused analysis of current Good Manufacturing Practices, inspection readiness, data integrity, and quality-system execution.
Noteworthy developments affecting manufacturers, CDMOs, and the 503A and 503B compounding environment.
03 / The archive
13 conversations on FDA guidance, enforcement, cGMP practice, and compounding—each summarized here so the substance is searchable, not just audible.
Subscribe via RSS feed
Nov 2, 2026 · 00:22:09
On this episode of The Regulatory Mix, we break down FDA’s updated Concept of Operations for Facility Evaluation and Inspection of Human Drugs and answer a deceptively simple question: After the investigator leaves, who is actually reviewing my inspection? The answer depends on the type of inspection and what FDA is evaluating.
Oct 28, 2026 · 00:18:09
On this episode of The Regulatory Mix, the discussion focuses on a major new policy shift affecting peptide compounding under Section 503A. HHS has announced an interim enforcement discretion policy allowing certain state-licensed pharmacies, federal facilities, and licensed physicians to compound drug products using six specified…
Oct 24, 2026 · 00:25:39
On this episode of The Regulatory Mix, the discussion goes inside one of the most visual, and often misunderstood, elements of sterile manufacturing: the airflow visualization study, better known as the smoke study.
Oct 18, 2026 · 00:23:27
On this episode of The Regulatory Mix, the discussion focuses on FDA’s updated 2026 guidance for biosimilar and interchangeable biological products and what it means for development strategy, product design, pediatric requirements, and postapproval manufacturing.
Oct 11, 2026 · 00:21:50
On this episode of The Regulatory Mix, the discussion focuses on PIC/S Recommendation PI 006-4, which entered into force on October 1, 2026, and what it means for qualification and validation across pharmaceutical manufacturing.
04 / Take the insight with you
Follow the show in your podcast app, keep up on LinkedIn, or subscribe through RSS.
From conversation to consulting
The podcast provides general information. For a specific inspection, FDA observation, enforcement response, or complex quality decision, Tailwind Pharma provides direct consulting support.